According to multiple recent market analyses, the global API market is experiencing steady growth. One comprehensive forecast ...

New sublingual delivery system designed to enhance bioavailability and speed of onset for major depressive and ...

Mumbai: Pharma major Lupin has announced the completion of a cGMP inspection carried out by the United States Food and Drug ...

Natco Pharma's Q3 consolidated net profit rose 14.3% YoY to ₹152 crore, while revenue increased by 36.3%, driven by higher export formulations and other operating income.

The Fine and Specialty Chemicals Market is entering a transformative phase of high-value innovation and application-specific customization, underpinned by specialty chemicals’ critical role as ...

Market valued at $16.86B in 2024, projected 4.20% CAGR growth driven by VOC regulation compliance, bio-based adoption, ...

HANGZHOU CITY, ZHEJIANG PROVINCE, CHINA, January 20, 2026 /EINPresswire.com/ -- The global fine chemicals industry is ...

Earnings before interest, tax, depreciation and amortisation (EBITDA) surged to ₹158.7 crore in Q3 FY26, up from ₹39 crore in the corresponding quarter last year. EBITDA margin improved sharply to 24.

Lupin Ltd reported a consolidated net profit of ₹1,175.6 crore in Q3 FY26, up 37.5% year-on-year, though down sequentially from Q2 FY26. Consolidated revenue rose 24.3% YoY to ₹7,167.5 crore.

Apimeds Pharmaceuticals is set to discuss a treatment for osteoarthritis using bee venom at a Type C meeting with the Food and Drug Administration.